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Abstract
Eph-ephrin system plays a central role in a large variety of human cancers. In fact, alterated expression and/or de-regulated
function of Eph-ephrin system promotes tumorigenesis and development of a more aggressive and metastatic tumour
phenotype. In particular EphA2 upregulation is correlated with tumour stage and progression and the expression of EphA2
in non-trasformed cells induces malignant transformation and confers tumorigenic potential. Based on these evidences our
aim was to identify small molecules able to modulate EphA2-ephrinA1 activity through an ELISA-based binding screening.
We identified lithocholic acid (LCA) as a competitive and reversible ligand inhibiting EphA2-ephrinA1 interaction
(Ki=49 mM). Since each ephrin binds many Eph receptors, also LCA does not discriminate between different Eph-ephrin
binding suggesting an interaction with a highly conserved region of Eph receptor family. Structurally related bile acids
neither inhibited Eph-ephrin binding nor affected Eph phosphorylation. Conversely, LCA inhibited EphA2 phosphorylation
induced by ephrinA1-Fc in PC3 and HT29 human prostate and colon adenocarcinoma cell lines (IC50=48 and 66 mM,
respectively) without affecting cell viability or other receptor tyrosine-kinase (EGFR, VEGFR, IGFR1b, IRKb) activity. LCA did
not inhibit the enzymatic kinase activity of EphA2 at 100 mM (LANCE method) confirming to target the Eph-ephrin protein-
protein interaction. Finally, LCA inhibited cell rounding and retraction induced by EphA2 activation in PC3 cells. In
conclusion, our findings identified a hit compound useful for the development of molecules targeting ephrin system.
Moreover, as ephrin signalling is a key player in the intestinal cell renewal, our work could provide an interesting starting
point for further investigations about the role of LCA in the intestinal homeostasis.
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Introduction
The Eph receptor tyrosine kinases belong to the largest family
of tyrosine kinase receptors. To date 16 members, across many
species, have been identified [1] and divided into 2 classes (A and
B), based on sequence homology of extracellular domain and on
their affinity for ephrin ligands. Ephrins are also divided into 2
groups: ephrins A are glycosylphosphatidyl-inositol (GPI)-linked
proteins anchored to cell membrane while ephrins B are
transmembrane proteins. Ephrins A usually bind to EphA
receptors and ephrins B preferentially bind to EphB receptors.
Eph-ephrin binding within the same class is highly promiscuous
and inter-class binding examples have also been reported [2,3].
The membrane-bound protein nature of ephrin ligands gives
particular features to this system. First of all, cell-cell contact is
needed to activate the system, even if ephrins A released or
cleaved from cells retain the ability to activate Eph receptors
[4,5,6]. Second, bidirectional signals are generated by Eph-
ephrin interaction: forward signals into the cells expressing Eph
receptors go along with reverse signals into the cells bearing
ephrin ligands. Finally, increasing evidence shows that not only
Eph receptors but also ephrins can transmit signals independently
of their interaction, through crosstalk with other signalling
pathways [7].
Eph-ephrin system has beenextensively studied in embryogenesis
where it plays a critical role in tissue boundaries formation and
neuronal circuits development[8,9].Moreover, several reports have
shown an implication of this system in functions like cell growth and
survival, cell attachment and migration, highlighting a possible
critical role in tumorigenesis, cancer progression, invasiveness and
metastasis. Among all Eph receptors, EphA2 is the most widely
studied in oncology field because of its expression and function in
several cancer types. In fact the EphA2 overexpression results in the
transformation of mammary epithelial cells [10] and has been
correlated with poor clinical prognosis in many studies [11,12,13].
High levels of this receptor have been found in several cancer
types including brain, lung, breast, ovarian, prostate, colorectal,
and kidney malignancies. Moreover ephrinA1, the physiological
EphA2 receptor ligand, is often downregulated when EphA2 is up-
regulated and vice versa [6,14].
For all these reasons EphA2 receptor represents a promising
target in cancer therapy and different strategies are under
evaluation by several research groups in order to develop specific
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interaction.
Although a first class of small molecule able to antagonize ephrin
binding to the EphA4 and EphA2 receptors has been recently
identified [15], the ephrin field remains essentially orphan of
pharmacological tools able to elucidate its physiopathological role.
With this in mind, we performed an ELISA binding assay
screening on an ‘‘in-house’’ chemical library (Table S1). This
approach aimed to identify scaffolds that might be utilized to
design chemical entities able to inhibit the interaction between
EphA2 extracellular domain and ephrinA1. The chemical library
includes drugs and endogenous bioactive molecules. The use of
drugs is very advantageous because of their already optimized
pharmacokinetic and toxicity profiles. On the other hand, the
discovery of new activities of physiological, bioactive compounds
can provide the basis for novel investigations in pathophysiological
fields. In the present work, we describe the discovery of lithocholic
acid (LCA), a secondary bile acid, as a novel competitive,
reversible antagonist of the Eph-ephrin system.
Methods
1. Reagents
All culture media and supplements were purchased from Lonza.
Recombinant proteins and antibodies were from R&D systems.
Cells were purchased from ECACC. Leupeptin, aprotinin, NP40,
MTT, tween20, BSA and salts for solutions were from Applichem;
bile acids, EDTA and sodium orthovanadate were from Sigma.
Human IgG Fc fragment was from Millipore (AG714).
2. Cell cultures
PC3 human prostate adenocarcinoma cells were grown in Ham
F12 supplemented with 7% fetal bovine serum (FBS) and 1%
antibiotic solution. HT-29 human colon adenocarcinoma cells
were maintained in EMEM supplemented with 10% FBS,
1%NEAA, 1% sodium piruvate and 1% antibiotic solution.
T47D human breast tumor cells were grown in RPMI 1640 with
10% FBS and 1% antibiotic solution. All cell lines were grown in a
humidified atmosphere of 95% air, 5% CO2 at 37uC.
3. ELISA screening and Ki/IC50 determination
Our chemical collection (Table S1) was stocked in a 20 mM
dimethyl sulfoxide (DMSO) solution and we performed binding
assay at a concentration of 200 mM. Only compounds displacing
more than 40% ephrinA1 from EphA2 receptor were considered
for a full concentration-binding curve. 96 well ELISA high binding
plates (Costar #2592) were incubated overnight at 4uC with
100 ml/well of 1 mg/ml EphA2-Fc (R&D 639-A2) diluted in sterile
PBS (0.2 g/l KCl, 8.0 g/l NaCl, 0.2KH2PO4, 1.15 g/l Na2HPO4,
pH 7.4). The day after wells were washed three times with
washing buffer (PBS +0.05% tween20, pH 7.5) and blocked with
300 ml of blocking solution (PBS +0.5% BSA) for 1 hour at 37uC.
Compounds were added to the wells at proper concentration in
1% dimethyl sulfoxide (DMSO) and incubated at 37uC for 1 hour.
Biotinylated ephrinA1-Fc (R&D BT602) was added at 37uC for
4 hours at 30 ng/ml in displacement assays or in a range from 1 to
2000 ng/ml in saturation studies. Wells were washed three times
and incubated with 100 ml/well Streptavidin-HRP (Sigma S5512)
solution (0.05 mg/ml in PBS supplemented with 0.5% BSA,
pH 7.4) for 20 minutes at room temperature, then washed again
for three times and incubated at room temperature with 0.1 mg/
ml tetra-methylbenzidine (Sigma T2885) reconstituted in stable
peroxide buffer (11.3 g/l citric acid, 9.7 g/l sodium phosphate,
pH 5.0) and 0.02% H2O2 (30% m/m in water), added
immediately before use. The reaction was stopped with 3N HCl
100 ml/well and the absorbance was measured using an ELISA
plate reader (Sunrise, TECAN, Switzerland) at 450 nm.
The IC50 value was determined using one-site competition non-
linear regression and Kd values of the curves with or without
antagonists were calculated using one-binding site non-linear
regression analysis with Prism software (GraphPad Software Inc.).
The Ki was obtained using Schild plot [16] where Log[DR-1] is a
function of the negative Log10 of the inhibitor concentration. The
Hill’s coefficient was calculated using linear fitting to evaluate
whether the inhibition was competitive or uncompetitive.
4. PC3 cell binding
96 well ELISA high binding plates were incubated overnight at
4uC with ephrinA1-Fc 1 mg/cm
2, 100 ml per well. The plates were
washed three times with PBS and blocked for 1 hour with BSA
1%. Cells were treated with proper concentration of substance or
DMSO 0.5% for 30 minutes in vials on a shaker. After that, plates
were washed with PBS and incubated with 100 ml5 610
5 cells/ml
for 1 hour at 37uC. Finally, plates were washed with PBS and
adhering cells were quantified using MTT colorimetric assay.
5. Cell lysates
Cells were seeded in 12-well plates at concentration of 10
5cells/
ml in complete medium until they reached ,40% confluence and
serum starved overnight. The day after cells were treated with
compounds under study, vehicle or standard drug, stimulated with
the proper agonist, rinsed with sterile PBS and solubilized in lysis
buffer. The lysates were resuspended and rocked at 4uC for 30
minutes and then centrifuged at 14000 xg for 5 minutes. The
protein content of supernatant was measured with BCA protein
assay kit (Thermo scientific), standardized to 200 mg/ml and
transferred into a clean test tube ready to be used.
6. Phosphorylated-EphA2, -EphB4 and –EGFR
EphA2-, EphB4- and EGFR-phosphorylation were measured in
cell lysates using DuoSetHIC Sandwich ELISA (RnD Systems,
#DYC4056, #DYC4057 and #DYC1095, respectively) follow-
ing manufacturer’s protocol. Briefly, 96 well ELISA high binding
plates (costar 2592) were incubated overnight at room temperature
with 100 ml/well of the specific capture antibody diluted in sterile
PBS to the proper working concentrations. The day after wells
were washed and blocked for 1 hour at room temperature. After
that, wells were washed and 100 ml/well of lysates were added at
room temperature for 2 hours; wells were washed and incubated
with Detection Antibody at room temperature for 2 hours. The
phosphorylation was revealed utilizing a standard HRP format
with a colorimetric reaction read at 450 nm.
7. VEGFR, IRKb and IGFR1b activity
Stimulant or inhibitory effects of LCA towards IRKb and
IGFR1b activity were tested using alpha Technology (PerkinEl-
mer, Waltham, MA, USA) in HepG2 or A431 cells, respectively.
Cells were seeded in microplates at 4610
4 cells/well and
preincubated for 5 min at 22uC in presence of either HBSS or
LCA. Cells were stimulated with 5 nM IGF1 or 100 nM insulin
for 10 minutes, lysed and a fluorescence acceptor (alphaLISA
protein A beads coated with anti-phospho-IRKb or -IGFR1b)
added for 2 hours. A fluorescence donor (streptavidin coupled-
beads) coated with an antibody towards IRKb or IGFR1b was
incubated for 2 hours and the signal was measured at
lex=680 nm and lem=500 nm and 600 nm using a microplate
reader (EnVision, Perkin Elmer, Waltham, MA, USA).
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activity were tested in HUVE cells using cellular dielectric
spectroscopy. Cells were seeded at 5610
4 cells/well into 96-well
plate, the following day growth media was exchanged with HBSS
buffer +20 mM HEPES and cells were allowed to equilibrate for
75 min with or without 100 mM LCA and stimulated with 0.1 nM
VEGF. Impedance measurement was monitored for 10 minutes.
VEGF receptor tyrosine kinase inhibitor II (Calbiochem-Merck,
Darmstadt, Germany) was used as a standard reference.
All results were expressed as a percent inhibition of the control
response to 5 nM IGF1, 100 nM insulin or 0.1 nM VEGF. These
assays were performed at CEREP (Celle L’Evescault, France).
7. Kinase assay
Evaluation of LCA effects on the kinase activity of human
EphA2 was performed by measuring the phosphorylation of the
substrate Ulight-TK peptide (50 nM) using the LANCE detection
method [17]. Staurosporine was used as reference compound.
8. MTT assay
Cell viability was evaluated using the MTT colorimetric assay.
Cells were plated in 96-well plates at a density of 10
5cells/ml and
the day after treated with compounds or 0.5% DMSO for 2, 24,
48, or 72 hours. MTT was added at the final concentration of
1 mg/ml and incubated for 2 hours. The resulting formazan
crystals were washed with PBS 100 ml/well and then solubilized
with DMSO 200 ml/well. The absorbance was measured at
550 nm using an ELISA plate reader and the results were
expressed as the ratio between absorbance of the cell treated with
the compounds and untreated cells.
9. PC3 cell rounding assay
PC3 cells were grown on 12-well culture plates and starved
overnight in Ham-F12 medium with 0.5% FBS. DMSO (final
concentration 0.25%) or compounds were incubated for 20 min,
before stimulation with 0.5 mg/ml ephrinA1-Fc or Fc for 30
minutes. During this time cells were observed and pictures were
taken from the same field, before and after incubation, under a
microscope (Leica, DM IL). Cell rounding was evaluated using
ImageJ program.
Results
Lithocholic acid was a competitive and reversible Eph-
receptor ligand
To identify compounds interfering with EphA2-ephrinA1
binding we immobilized EphA2-Fc- ectodomain on proper ELISA
plates and binding of biotinylated-ephrin-A1-Fc was detected
using the colorimetric reaction developed by streptavidine-HRP
and tetramethylbenzidine.
Selectivity and specificity of the assay were tested using not-
biotinylated ephrin-A1-Fc as a ligand of the EphA2-Fc receptor
(Figure S1). As expected, not-biotinylated ephrin-A1-Fc compet-
itively inhibited EphA2-biotinylated-ephrin-A1 binding with a Ki
of 102 ng/ml and a Hill coefficient of 1.19. Furthermore, Fc alone
did not interfere with the binding process at any concentration.
All the compounds of the chemical collection were incubated for
1 hour at the concentration of 200 mM and only lithocholic acid
resulted to significantly reduce EphA2-ephrinA1 binding.
We repeated the experiment testing LCA together with bile acid
analogues: cholic (CA), deoxycholic (DCA) and chenodeoxycholic
(CDCA). CA, DCA and CDCA did not displaced EphA2-
ephrinA1 binding whereas LCA decreased it by 68.2%64.3. In
order to calculate the inhibitory concentration reducing binding of
50% (IC50) we charted a displacement curve using increasing
concentration of LCA (in the range of 12.5–400 mM) towards
biotinylated-ephrinA1-Fc at a concentration corresponding to its
KD. In these conditions we obtained a dose-dependent displace-
ment and we calculated a pIC50 of 4.2460.068 (corresponding to
an IC50 of 57 mM, Figure 1A). To evaluate the nature of the
antagonism we plotted saturation curves of EphA2-ephrinA1
binding in presence of increasing concentrations of LCA
(Figure 1B). We calculated the KD or the apparent KD of each
curve and we drew a Schild plot, where Log[DR-1] is a function of
the –Log10[inhibitor] [16] (Figure 1C). We obtained a well-
interpolated regression line (r
2=0.9664) having a slope of 0.8618.
A slope between 0.8 and 1.2 is associated with a competitive
binding. Finally, the pKi resulting from the intersection of the
interpolated line with the X-axis resulted to be equal to 4.3160.03
(corresponding to a Ki of 49 mM). We repeated displacement
experiments incubating 200 mM LCA for 1 hour and washing
some wells before adding 50 ng/ml ephrinA1-Fc. The displace-
ment was detected only where the washing was not performed,
suggesting the reversibility of the LCA binding to EphA2-
ephrinA1 system (Figure 1D).
Next, we tested LCA activity towards all the EphA and EphB
kinases using biotinylated ephrinA1-Fc and biotinylated ephrinB1-
Fc, respectively, at their KD concentration. LCA showed to be a
promiscuous ligand of EphA and EphB receptor subfamilies,
suggesting the existence of a common mechanism of interference
towards Eph-ephrin binding (Fig 2).
We also simulated in vivo conditions immobilizing ephrinA1-Fc
on high binding plates and performing adhesion with PC3 cells. In
these experiments ephrinA1-Fc effectively mediated cell adhesion
through EphA2-ephrinA1 interaction. In fact, preincubation with
4 mg/ml EphA2-Fc or ephrinA1-Fc completely abolished PC3
adhesion. Similarly, LCA dose-dependently inhibited PC3 adhe-
sion to ephrinA1-Fc (Fig 3B). The experiment was repeated on
uncoated standard cell culture plates where aspecific adhesion was
mediated by multiple factors (selectins, integrins, cadherins) and
not by Eph-ephrin interaction [18]. Figure 3A reports that neither
ephrinA1-Fc nor LCA inhibited aspecific cell adhesion. However,
a discrepancy between affinity of LCA in binding assays and its
potency in adhesion study is noticed. Such a divergence could be
related to the differences between the ELISA-binding study and
the functional adhesion study due to, incubation times (1 hour
+4 hours for binding; 30 minutes +1 hour for adhesion), biological
system (only proteins for binding; cells and proteins for adhesion)
and sensitivity of the revelation method (HRP for binding; MTT
for adhesion).
LCA acid inhibited Eph-kinases phosphorylation at not-
cytotoxic concentrations
Functional studies were performed in cultured cells to evaluate
agonist or antagonist properties of LCA and other bile acids at
Eph receptors. We used PC3 human prostate adenocarcinoma
and HT29 human colon adenocarcinoma cells as a model for their
known ability to naturally express EphA2 [18,19]. Moreover, PC3
are a well established model to study Eph-ephrin pharmacology
whereas HT29 cells are commonly used to study the physiological
role of bile acids [20].
In these studies we stimulated EphA2 phosphorylation with
0.25 mg/ml ephrinA1-Fc on PC3 or HT29 cells, in presence or
absence of bile acids. Dasatinib 1 mM was used as reference
compound being a multikinase inhibitor endowed with a high
potency towards Eph kinases [21].
Consistently with binding studies, 100 mM CA, DCA and
CDCA were inactive towards Eph kinases phosphorylation both
Lithocholic Acid and Ephrin System
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the other hand data in figures 4A-F demonstrated that LCA is an
EphA2 antagonist inhibiting in a dose-dependent manner
ephrinA1-Fc induced EphA2 phosphorylation with an
IC50=48mM and 66 mM on PC3 and HT29 cells, respectively.
As LCA showed to be a promiscuous ligand of EphA and EphB
receptor subfamilies we tested LCA activity against EphB4
phosphorylation on T47D breast cancer cells induced by 3 mg/
ml ephrinB2-Fc, preclustered with 0.3 mg/ml of IgG Fc fragment.
LCA dose-dependently inhibited EphB4 phosphorylation with an
IC50 of 141 mM(Figure 4G–I). This value is higher than the value
obtained for EphA2 phosphorylation and it is consistent with
binding data where LCA has a 2-fold lower affinity towards EphB
receptors when compared to EphA receptors. MTT assay
demonstrated that concentrations tested in phosphorylation
studies were not cytotoxic (Figure S2).
LCA antagonized Eph-kinase phosphorylation inhibiting
protein-protein interaction
In order to exclude a direct inhibition of LCA with Eph kinase
domain, an enzyme-based assay was performed. Briefly, incuba-
tion of recombinant EphA2-kinase induced the phosphorylation of
a proper substrate (Ulight-TK peptide 50 nM) which was
recognized by an Europium-labeled anti-phospho antibody and
resulted in light emission (LANCE detection method, [17]).
Incubation of the protein with staurosporine, used as reference
compound, inhibited kinase activity (IC50=93 nM), whereas
incubation with LCA up to 100 mM did not modify enzymatic
activity (Fig 5).
LCA did not affect EGFR, VEGFR, IRKb or IGFR1b activities
In order to assess the specific interaction of LCA with Eph-
kinases we performed functional assays on other receptor tyrosine
kinases (EGFR, VEGFR, IRKb or IGFR1b). LCA 100 mM was
completely inactive when tested towards the phosphorylation of
EGF receptors induced by EGF both in PC3 and HT29 cells
(Fig 6A,B) whereas the EGFR kinase inhibitor gefitinib (10 mM),
used as reference compound, completely abolished response to
EGF. Similarly LCA failed to affect activity of VEGFR, IRKb or
IGFR1b both when tested as an agonist or an antagonist (Fig 6C).
LCA antagonized EphA2-dependent PC3 cell rounding
Previous studies showed that PC3 cells express mainly EphA2
receptors and their activation lead to cell retraction and rounding
Figure 1. Lithocholic acid competitively inhibited EphA2-ephrinA1 binding. 96 well ELISA high binding plates were incubated O/N with
EphA2-Fc and the following day washed and blocked with PBS +0.5% BSA for 1 hour at 37uC. Compounds were added in the wells at proper
concentrations 1 hour before the addition of biotinylated ephrinA1-Fc. After 4 hours wells were washed and incubated with a streptavidin-HRP
solution for 20 minutes at room temperature. Wells were washed again and incubated with tetra-methylbenzidine. The reaction was stopped with 3N
HCl and the absorbance was measured at 450 nm. A, lithocholic acid dose-dependently displaced binding of ephrin-A1-Fc ectodomain from
immobilized EphA2-Fc ectodomain. B, binding of ephrin-A1-Fc ectodomain to immobilized EphA2-Fc ectodomain in presence of different
concentration of lithocholic acid. C, The dissociation constants (Kd) from the previous plot were used to calculate Log (Dose-ratio - 1) and to graph
the Schild plot. pKi of lithocholic acid was estimated by the intersection of the interpolated line with the X-axis. The slope of the interpolated line can
be related to the nature of the binding. A slope between 0.8 and 1.2 is related to a competitive binding whereas higher numbers are related to non-
specific interactions. D, EphA2-ephrinA1 binding in presence of 200 mM LCA with or without washing three times with PBS.
doi:10.1371/journal.pone.0018128.g001
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Fc ectodomain from immobilized EphA-Fc ectodomains. B, lithocholic acid dose-dependently displaced binding of ephrin-B1-Fc ectodomain from
immobilized EphB-Fc ectodomains. Data are the means of at least three independent experiments 6 st. err.
doi:10.1371/journal.pone.0018128.g002
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whether LCA was able to inhibit PC3 cell rounding induced by
0.5 mg/ml ephrinA1-Fc. The results (Fig 7) showed that LCA
blocked cell rounding at 100 mM, concentration inhibiting
completely EphA2 phosphorylation, while it was inactive at
10 mM, subthreshold concentration towards EphA2 phosphoryla-
tion. Neither DMSO 0.25% nor LCA alone induced changes in
cell morphology when incubated with Fc for 30 minutes.
Discussion
In the present work we showed for the first time the interaction
of lithocholic acid (LCA), a secondary bile acid, with Eph-ephrin
system. We demonstrated that LCA caused a reversible and
competitive displacement of the biotinylated ligand ephrinA1-Fc
from the receptor EphA2-Fc in cell-free binding studies and we
pointed out the antagonistic properties of LCA in phosphorylation
studies in different cell lines.
Bile acids had been considered for long time only as detergent
molecules necessary for lipid solubilization and absorption in the
intestine during digestion. However, many studies have explored
the hypothesis that bile acids also work as regulatory molecules. A
recent paper [20] used bile acid enantiomers to differentiate their
receptor- and non-receptor-mediated effects in HT29 and
HCT116 colon cancer cells. It definitely proved that bile acid-
induced cytotoxicity and apoptosis is enantiospecific and correlates
with a receptor interaction rather than aspecific detergent
properties. Other papers described specific interaction of bile
acids with the nuclear farnesoid X receptor, mainly involved in
hepatic lipid and glucose metabolism [22] and with the G protein
coupled receptor TGR5 whereby they induce intracellular cAMP
increase in CHO cells [23].
Consistently, our work suggests that LCA can act through the
interaction with specific receptors. In fact we provided evidence of a
competitive antagonism towards Eph-ephrin binding. First of all we
obtained the proper displacement of saturation curves, the proper
slopeoftheSchildplotandthereversibilityofthe binding.Insecond
place LCA inhibited Eph-kinase phosphorylation induced by
ephrinA1-Fc on PC3 and HT29 cell lines but it did not affect
enzymatic activity confirming to target the Eph-ephrin protein-
Figure 3. Lithocholic acid dose-dependently inihibited PC3 adhesion to ephrinA1-Fc. 96-wells plates for cell culture were untretaed (A) or
coated with 1 mg/cm
2 ephrinA1-Fc (B) overnight. PC3 cells were treated with the indicated compounds for 30 minutes in a tube and let to adhere for
60 minutes on the wells. Cell adhesion is reported normalizing adhesion of Fc to 100%. LCA concentrations are reported as mM. Data are the means of
at least three independent experiment 6 st. err. One-way ANOVA followed by Dunnet’s post test was performed comparing Fc to all other column.
No significant differences were detected for data in graph A. *, p,0.05, **,p,0.01.
doi:10.1371/journal.pone.0018128.g003
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RTKs such as EGFR, VEGFR IRKb, IGFR1b in cellular
functional studies demonstrating that LCA interfered neither with
kinase domain nor with protein-protein interaction of these RTKs.
Moreover, the Kiof LCA towards EphA2-ephrinA1interaction was
six times lower than its critical micelle concentration [24], LCA was
devoid of any toxicity at the studied concentrations and both
binding and functional tests reported the same range of LCA
activity includedbetween20 to 100 mM. Finally,structurallyrelated
bile acids bearing only minor chemical modifications on position 7-
OH (CDCA), 12-OH (DCA) or 7- and 12-OH (CA) were
completely inactive both in binding and phosphorylation studies.
Since Eph–ephrin binding is highly promiscuous also LCA does
not discriminate Eph-receptor subclasses A and B. Therefore we
can speculate an interaction with a highly conserved region
essential for both EphA and EphB receptor binding to their
physiological ligands. Ephrin recognition by Eph receptors is
mediated by ephrin G–H loop (key) that inserts into a hydrophobic
Eph receptor channel shaped by D–E and J–K loops (lock). [25].
Taken together these evidences suggest an interference of LCA
with the proper full insertion of the ephrin G–H loop into the Eph-
receptor hydrophobic channel. Structural studies will be essential
to clarify the dynamic of this interaction.
Figure 4. Lithocholic acid dose-dependently inhibited Eph-kinases phosphorylation. EphA2 phosphorylation was induced by 0.25 mg/ml
ephrinA1-Fc in PC3 (A, B, C) or HT29 cells (D, E, F). EphB4 phosphorylation was stimulated with 3 mg/ml ephrinB2-Fc, preclustered with 0.3 mg/ml IgG
Fc fragment on T47D cells (G, H, I). Cells were pretreated for 20 minutes with 1% DMSO, 100 mM bile acids or the indicated concentrations (mM) of LCA
and stimulated for 20 minutes with ephrinA1/B2-Fc (+) or Fc alone(2) as a control. Phospho-EphA2/B4 levels are relative to ephrinA1/B2-Fc+DMSO.
Data are the means of at least three independent experiment 6 st. err. One-way ANOVA followed by Dunnet’s post test was performed comparing Fc
to all other columns for Fig A, D, G and ephrinA1-Fc+DMSO to all other columns for Fig B,C,E, F, H, I. *, p,0.05, **, p,0.01.
doi:10.1371/journal.pone.0018128.g004
Figure 5. Lithocholic acid did not modify EphA2 enzymatic
activity. Recombinant human EphA2 enzyme activity was evaluated with
LANCEH method using ATP and Ulight-TK peptide as substrate (http://las.
perkinelmer.com/Catalog/CategoryPage.htm?CategoryID=LANCE+Rea
gents). Human EphA2 kinase was previously incubated with 100 mM
LCA, 1 mM staurosporine or 1% DMSO (control) for 30 minutes. T-test
was performed comparing LCA and staurosporine to control.
**,p,0.01.
doi:10.1371/journal.pone.0018128.g005
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with a higher affinity towards ephrin A system than ephrin B
system. Functional studies, carried out on different cell lines,
showed that LCA is an antagonist of Eph receptors, because it was
able to inhibit the phosphorylation of both EphA2 and EphB4
receptors when stimulated with ephrinA1-Fc and ephrinB2-Fc,
respectively. Notably, in accordance to binding studies, LCA
showed to have a higher efficacy in inhibiting EphA2 phosphor-
ylation than EphB4 phosphorylation.
The inhibition of Eph-ephrin system could be very useful in the
regulation of tumor progression. In fact, several studies highlighted
an important role for EphA2-ephrinA1 and EphB4-ephrinB2
interaction in tumor angiogenesis [7]. Furthermore, EphA2 or
EphB4 inhibition could reduce ameboid-type migration of cancer
cells and could stabilize epithelial adherens junctions in various
cancer cell lines, as suggested by Fang and Yang [26,27].
Moreover, the present work showed that LCA was able to
inhibit cell rounding and retraction in PC3 cell line upon EphA2
Figure 6. Lithocholic acid did not affect EGFR, VEGFR, IRKb or IGFR1b activity. A, B) EGFR phosphorylation was induced by 30 ng/ml and
10 ng/ml EGF on PC3 (A) and HT29 (B) cells, respectively. Cells were pretreated for 20 minutes with 1% DMSO, 100 mM LCA or 10 mM gefitinib and
stimulated for 20 minutes with EGF. Phospho-EGFR levels are relative to EGF+DMSO. Data are the means of at least three independent experiments 6
st. err. T-test was performed comparing Fc to LCA and EGF+DMSO to EGF+LCA and EGF+gefitinib. **,p,0,01. C) HUVE, HepG2 or A431 cells, were
stimulated for 10 minutes with 0.1 nM VEGF, 5 nM IGF1 or 100 nM insulin, respectively, in presence of 100 mM LCA or the proper inhibitor as a
reference (1 mM VEGFR inhibitor II or 10 mM AG538). Data are the means of two experiments 6 st. err. T-test was performed comparing ctr to other
column of the same receptor. **,p,0.01.
doi:10.1371/journal.pone.0018128.g006
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the effects mediated by EphA2. The inhibition of EphA2 could be
advantageous in cancer therapy whenever EphA2 activation
mediates tumor progression as previously demonstrated on
mammary tumors and melanoma cells [28,29]. Currently, many
strategies to block EphA2 signaling have been explored. Inhibition
of EphA2 activation by soluble EphA receptors, binding with
antibody or downregulation with siRNA resulted in decrease of
cell adhesion, angiogenesis, tumor growth and metastasis,
demonstrating that EphA2 may be an important target for anti-
tumorigenic and anti-angiogenic therapies [30,31,32]. High
affinity peptides binding to EphA2 receptors were identified by
means of a phage library screening. Binding peptides shared the
wxxw motif where w is an aromatic amino acid and x is a non-
conserved amino acid [33]. Unfortunately, peptides, siRNA and
antibodies are quite hard to use in any human therapy because of
their very unfavorable pharmacokinetic and pharmacodynamic
profiles. On the other hand, low molecular weight ligands still
represent a very valuable way to produce and administer drugs.
For this reasons our discovery can be a starting point for future
research aimed at the development of Eph-ephrin targeting
molecules. In fact modulation of the pharmacophore elements
present in bile acids could provide high affinity binding molecules,
as previously testified by the development of TGR5 and FXR
agonists [34].
In addition to the pharmacological features our discovery
suggests intriguing pathophysiological implications. In fact, the
expression levels of Eph-receptors and ephrin-ligands have a
critical role in the organizing cell renewal of the intestine [35,36].
As lithocholic acid fecal concentration is about 2 mM [37], it is
reasonable to suppose an involvement of this secondary bile acid
with ephrin system signaling in vivo. Consequently, LCA could play
a role in the intestinal homeostasis and an alteration of its
physiological amount could modify the expression and the
signaling of ephrin receptors and ligands. In this way the correct
segregation, proliferation and differentiation mechanisms, under-
lying the tissue homeostasis, could be alterated. Therefore, our
findings could be useful for further studies aimed to explain the
correlation between the concentration of fecal secondary bile acids
(mainly DCA and LCA) and the colorectal cancer incidence,
highlighted by several epidemiology studies [38,39,40], but whose
molecular mechanisms are far to be clear.
Figure 7. Lithocholic acid antagonized EphA2 dependent PC3 cell rounding. Serum starved PC3 cells were stimulated with 0.5 mg/ml
ephrinA1-Fc or Fc for 30 minutes in presence of DMSO or LCA preincubated for 20 minutes. A, Morphological changes of PC-3 cells induced by
ephrinA1-Fc or Fc treatment in presence of LCA 100 mM, LCA 10 mM and DMSO 0.25% added 20 minutes before. Cell images were collected from the
same field at time 0 and 30 minutes using a digital camera mounted on a Leica DM IL microscope. B, Histogram showing the average percentage of
retracting cells 30 minutes after a treatment with ephrinA1-Fc or Fc in presence of LCA 100 mM, LCA 10 mM and DMSO 0.25% preincubated for 20
minutes. Cells, which rounded their shape and having an area less than 20% of the initial value, were scored as retracting. Data are the means of at
least three independent experiments 6 st. err. One-way ANOVA followed by Dunnet’s post test was performed comparing ephrinA1-Fc+DMSO to all
other columns. *, p,0.05, **,p,0.01.
doi:10.1371/journal.pone.0018128.g007
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ephrinA1-Fc binding to EphA2. The Calculated Ki was 102 ng/
ml and the Hill slope was 1.19.
(PDF)
Figure S2 Cytotoxicity of bile acids on PC3, HT29 and T47D
cells after 2 hours of incubation with the indicated compounds.
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